Deconstructing cytisine: The syntheses of (±)-cyfusine and (±)-cyclopropylcyfusine, fused ring analogs of cytisine

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 7, 2008, Pages 2316-2319

  Yohannes, Daniel ^a   Procko, Kristen ^a   Lebel, Lorraine A ^a   Fox, Carol B ^a   O'Neill, Brian T ^a  

^a PFIZER INC   (United States)

Author keywords

( ) Cyfusine; ( ) Cytisine; ( 3)2 ( 4)3; ( 4)2( 2)3*; 3 + 2 cycloaddition; Cyclopropanation; Cyfusine; Cytisine; nAChR; Nicotinic acetylcholine receptor; Pyridone

Indexed keywords

CYCLOPROPANE DERIVATIVE; CYCLOPROPYLCYFUSINE; CYFUSINE; CYTISINE; EPIBATIDINE; NATURAL PRODUCT; NICOTINE; NICOTINIC AGENT; NICOTINIC RECEPTOR; PYRIDINE DERIVATIVE; PYRIDONE DERIVATIVE; PYRROLE DERIVATIVE; UNCLASSIFIED DRUG; VARENICLINE;

ARTICLE; BINDING AFFINITY; CYCLIZATION; CYCLOADDITION; CYCLOPROPANATION; DRUG SYNTHESIS; HYDROGENATION;

ALKALOIDS; AZOCINES; CYCLIZATION; CYCLOPROPANES; HETEROCYCLIC COMPOUNDS, 3-RING; MODELS, CHEMICAL; PYRIDONES; PYRROLES; QUINOLIZINES; RECEPTORS, NICOTINIC; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 41149113617     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.02.078     Document Type: Article

References (48)

1. Partheil A. Arch. Pharm. (Weinheim, Ger.) 232 (1894) 161
2. Ing H.R. J. Chem. Soc. (1932) 2778
3. Whiting P., and Lindstrom J. Proc. Natl. Acad. Sci. U.S.A. 8 (1987) 595
4. Flores C.M., Rogers S.W., Pabreza L.A., Wolfe B.B., and Kellar K.J. Mol. Pharmacol. 41 (1992) 31
5. Hall M., Zerbe L., Leonard S., and Freedman R. Brain Res. 600 (1993) 127
6. Happe H.K., Peters J.L., Bergman D.A., and Murrin L.C. Neuroscience 62 (1994) 929
7. Luetje N., Charles W., and Patrick Jim. J. Neurosci. 11 (1991) 837
8. Heinemann S.F., and Papke R.L. Mol. Pharmacol. 45 (1994) 142
9. Anderson D.J., and Arneric S.P. Eur. J. Pharm. 253 (1994) 261
10. Scharfenberg, G.; Benndorf, S.; Kempe, G. Cytisin (Tabex®) als medikamentöse Raucherentwöhnunshilfe. Dtsch. Gesund-heitsw. 1971, 26, 463.
11. Van Tamelen E.E., and Baran J.S. J. Am. Chem. Soc. 80 (1958) 4659
12. Bohlmann F., Englisch A., Ottawa N., Sander H., and Weise W. Angew. Chem. 67 (1955) 708
13. Govindachari T.R., Rajadurai S., Subramanian M., and Thyagarajan B.S. J. Chem. Soc. (1957) 3839
14. O'Neill B.T., Yohannes D., Bundesmann M.W., and Arnold E.P. Org. Lett. 2 (2000) 4201
15. Coe J.W. Org. Lett. 2 (2000) 4205
16. Nshimyumukiza P., Cahard D., Rouden J., Lasne M.-C., and Plaquevent J.-C. Tetrahedron Lett. 42 (2001) 7787
17. Botuha C., Galley C.M.S., and Gallagher T. Org. Biol. Chem. 2 (2004) 1825
18. Stead D., O'Brien P., and Sanderson A.J. Org. Lett. 7 (2005) 4459
19. Danieli B., Lesma G., Passarella D., Sacchetti A., Silvani A., and Virdis A. Org. Lett. 6 (2004) 493
20. Honda T., Takahashi R., and Namiki H. J. Org. Chem. 70 (2005) 499
21. A comprehensive review of the total syntheses of cytisine has recently been published:. Stead D., and O'Brien P. Tetrahedron 63 (2007) 1885
22. Coe J.W., Brooks P.R., Vetelino M.G., Wirtz M.C., Arnold E.P., Sands S.B., Davis T.I., Lebel L.A., Fox C.B., Shrikhande A., Schaeffer E., Rollema H., Lu Y., Mansbach R.S., Chambers L.K., Rovetti C.C., Schulz D.W., Tingley III F.D., and O'Neill B.T. J. Med. Chem. 48 (2005) 3474
23. Breining S.R. Curr. Top. Med. Chem. 4 (2004) 609
24. Olivo H.F., and Hemenway H.S. Org. Prep. Proc. Int. 34 (2002) 1
25. O'Neill, B. T. U.S. Patent WO 98/18798, 1998.
26. Rouden J., Seitz T., Lemoucheux L., and Lasne M.-C. J. Org. Chem. 69 (2004) 3787
27. Carbonnelle E., Sparatore F., Canu-Boido C., Salvagno C., Baldani-Guerra B., Terstappen G., Zwart R., Vijverberg H., Clementi F., and Gotti C. Eur. J. Pharm. 471 (2003) 85
28. Slater Y.E., Houlihan L.M., Maskell P.D., Exley R., Bermudez I., Lukas R.J., Valdivia A.C., and Cassels B.K. Neuropharmacology 44 (2003) 503
29. Boido C., Tasso B., Boido V., and Sparatore F. Farmaco 58 (2003) 265
30. Roger G., Lagnel B., Rouden J., Besret L., Valette H., Demphel S., Gopisetti J.M., Coulon C., Ottaviani M., Wrenn L.A., Letchworth S.R., Bohme G.A., Benavides J., Lasne M.-C., Bottlaender M., and Dolle F. Bioorg. Med. Chem. 11 (2003) 5333
31. Imming P., Klaperski P., Stubbs M.T., Seitz G., and Gundisch D. Eur. J. Med. Chem. 36 (2001) 375
32. Marriere E., Rouden J., Tadino V., and Lasne M.-C. Org. Lett. 2 (2000) 1121
33. Boido C., and Sparatore F. Farmaco 54 (1999) 438
34. Lin N.H., and Meyer M.D. Exp. Opin. Ther. Pat. 8 (1998) 991
35. Chellappan S.K., Xiao Y., Tueckmantel W., Kellar K.J., and Kozikowski A.P. J. Med. Chem. 49 (2006) 2673
36. Blackall K.J., Hendry D., Pryce R.J., and Roberts S.M. J. Chem. Soc., Perkin Trans. 1 (1995) 2767
37. Fitch R.W., Kaneko Y., Klaperski P., Daly J.W., Seitz G., and Guendisch D. Bioorg. Med. Chem. Lett. 15 (2005) 1221
38. Chellappan S.K., Xiao Y., Tueckmantel W., Kellar K.J., and Kozikowski A.P.J. J. Med. Chem. 49 (2006) 2673
39. Kozikowski A.P., Chellappan S.K., Xiao Y., Bajjuri K.M., Yuan H., Kellar K.J., and Petukhov P.A. Chem. Med. Chem. 2 (2007) 1157
40. Shishkin D.V., Shaimuratova A.R., Lobov A.N., Baibulatova N.Z., Spirikhin L.V., Yunusov M.S., Makara N.S., Baschenko N.Zh., and Dokichev V.A. Chem. Nat. Compd. 43 (2007) 190
41. For aromatic analogs of the pyridone ring, see:. Coe J.W., Vetelino M.G., Bashore C.G., Wirtz M.C., Brooks P.R., Arnold E.P., Lebel L.A., Fox C.B., Sands S.B., Davis T.I., Schulz D.W., Rollema H., Tingley F.D., and O'Neill B.T. Bioorg. Med. Chem. Lett 15 (2005) 2974
42. A very interesting N → C acyl migration on (-)-cytisine has been reported:. Rouden J., Ragot A., Gouault S., Cahard D., Plaquevent J.-C., and Lasne M.-C. Tetrahedron: Asymmetry 13 (2002) 1299
43. The lowest energy conformation of 11 was compared to the crystal structure of 1 (Overall RMS of overlay = 0.61 Å) utilizing Chem3D Ultra (v.10.0), available from CambridgeSoft Inc., 100 CambridgePark Drive, Cambridge, MA 02140 USA. The X-ray structure of (-)-cytisine was retrieved from:. Freer A.A., Robins D.J., and Sheldrake G.N. Acta Cryst. C43 (1987) 1119
44. Made by the method of. Cossy J., and Pete J.-P. Bull. Soc. Chim. Fr. (1979) 559
45. Available from the Aldrich Chemical Company, Cat # 42,069-7.
46. Compound 7 is oxidatively unstable, converting completely to the pyrrole over several days when exposed to air.
47. The assays were conducted according to the protocols in the supplementary information in Ref. 11.
48. 3, 400 MHz) 7.51 (t, 1H), 6.35 (t, 1H), 6.39 (d, J = 8.7 Hz, 1H), 4.23(d, J = 6.6 Hz, 2H), 3.90 to 3.82 (m, 2H), 3.65 to 3.53 (m, 2H), 1.49 (d, J = 5.8 Hz, 1H), 1.45 (s, 9H), 1.32 (d, J = 5.8 Hz, 1H) ppm. Mass spectrum (APCI) m/e 289 p + 1).